Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Many people experience a serious return of appetite, cravings and weight after coming off Ozempic, and having read far too ...

Even those using appetite-suppressing jabs such as Ozempic and Wegovy need a similar mindset ... will benefit from implementing tricks and strategies that help them to keep extra pounds at bay, and ...

You can take Wegovy (semaglutide) in carry-on luggage when flying, but you’ll need to declare it at security for screening. It’s also important to keep Wegovy within certain temperature ranges ...

But leading treatments like Zepbound and Novo Nordisk’s Wegovy are injectable. Drugmakers are eager to develop an easier-to-take pill version for patients who don’t want to deal with needles ...

“Everybody’s on pins and needles because we don’t know exactly what’s going to come out of this,” Smart said. Football rosters are expected to be capped at 105 players, but Smart said ...

The April 7 memo, confirmed as authentic by the Air Force, rescinds the family days -- extra leave granted around federal holidays that can be used for four-day weekends -- for troops in both ...

John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access to GLP-1 medications, such as Ozempic and Wegovy, for millions of Medicare ...

The rise of weight-loss drugs like Ozempic and Wegovy have upended WeightWatchers business model, which was based around selling low-calorie foods and diet advice to overweight people.

UPDATE: The PS Plus Extra and Premium games have been revealed in full. In addition to Lost Records: Bloom & Rage – Tape 2 and Blue Prince, PS Plus Extra subscribers can download and play ...